Pathology Consultants of New Mexico

Pathology Consultants of New Mexico was paid $18.01M by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 28% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	39,188	$1.27M
2019	42,832	$1.43M
2020	60,781	$3.07M
2021	106,201	$4.12M
2022	94,606	$3.78M
2023	57,435	$2.19M
2024incomplete	50,667	$2.15M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	28%	58,973	53,110	$5.01M
88305	Level IV - Surgical pathology, gross and microscopic examination	11%	28,284	27,081	$2.00M
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	7.2%	46,441	46,283	$1.31M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	6.9%	33,260	33,095	$1.24M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.9%	33,246	33,077	$1.24M
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	6.7%	32,605	32,483	$1.21M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.8%	40,705	36,265	$1.05M
81513		5.3%	7,622	7,499	$951K
87481		3.8%	9,377	8,287	$679K
99000		3.1%	79,416	75,783	$556K
88307		2.6%	4,114	4,026	$467K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	2.5%	12,054	11,900	$452K

20 more codes

88312		1.9%	10,297	$344K
88342		1.1%	2,622	$197K
88304		1.1%	7,430	$192K
88141		<1%	7,169	$171K
87625		<1%	3,446	$143K
88341		<1%	1,302	$132K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	6,176	$111K
87660		<1%	4,631	$95K
87480		<1%	4,607	$95K
87510		<1%	4,595	$94K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	2,057	$88K
85060		<1%	1,686	$39K
88142		<1%	1,628	$35K
88112		<1%	946	$32K
S9999	Sales tax	<1%	4,090	$31K
87511		<1%	441	$17K
88311		<1%	917	$16K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	463	$12K
88302		<1%	647	$8K
88300		<1%	463	$5K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMOORES, LISA (CEO/ MANAGING PARTNER)